Skip to main content
Clinical Trials/NCT02319915
NCT02319915
Completed
Early Phase 1

Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.

Brugmann University Hospital1 site in 1 country14 target enrollmentFebruary 18, 2015

Overview

Phase
Early Phase 1
Intervention
Tranexamic Acid
Conditions
Knee Prosthesis
Sponsor
Brugmann University Hospital
Enrollment
14
Locations
1
Primary Endpoint
The pharmacokinetic profile of tranexamic acid
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Evaluate the pharmacokinetic profile of tranexamic acid injected intra-articularly with or without adrenaline, in a population of patients undergoing knee replacement.

Detailed Description

Orthopedic population, especially during a knee surgery, is at risk of significant bleeding and blood transfusion in the perioperative period. Tissue damage is associated with the activation of a cascade of mechanisms, in which the activation of the fibrinolyse plays an important role. This is why anti-fibrinolytic agents are regularly used in this context to reduce the perioperative bleeding and the use of blood transfusions. In the majority of cases, tranexamic acid, an analogue agent of lysine, is administered by an intravenous injection and more recently, by an intra-articular injection. Several questions however remain unanswered. * what is the clearance of this substance ? * does an intra-articular resorbtion exist, resulting in a plasmatic rate of the substance ? If yes, what is the plasmatic rate ? * Is the intra-articular effect of tranexamic acid predominant compared to its systemic effect ? * Does the addition of adrenalin increase the effect of the tranexamic acid by acting on its absorption ? The efficacy, safety and better administration route of the tranexamic acid remain unknown when injected intra-articularly. The goal of this study is to realize the first pharmacokinetic study after an intra-articular injection of tranexamic acid, alone of along with adrenalin, in a knee neo-articulation.

Registry
clinicaltrials.gov
Start Date
February 18, 2015
End Date
March 14, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Philippe VAN DER LINDEN

Pr, MD, Head of clinic

Brugmann University Hospital

Eligibility Criteria

Inclusion Criteria

  • programmed PTG, right or left
  • surgery planned within the CHU Brugmann Hospital (Dr Reynders)
  • ASA I to ASA III
  • Signed informed consent within the patient file

Exclusion Criteria

  • re-do surgery
  • urgent or multiple surgery
  • ASA IV or higher
  • Patients with a BMI superior or equal to 40
  • Patient is a Jehovah Witness
  • Allergy or contra-indication to tranexamic acid
  • Coagulation troubles, defined as: Platelet count \< 80 000/mm3 and/or PTT \<70% and/or aPTT \>45s and/or Fibrinogen \<100mg/dL
  • Preoperatory renal insufficiency defined as Creatinin \> 3mg/dL and/or Dialysis patients.

Arms & Interventions

Tranexamic acid

Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection.

Intervention: Tranexamic Acid

Tranexamic acid + adrenalin

Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.

Intervention: Tranexamic Acid

Tranexamic acid + adrenalin

Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.

Intervention: Adrenalin

Outcomes

Primary Outcomes

The pharmacokinetic profile of tranexamic acid

Time Frame: 24h

Blood sampling will be performed to establish the pharmacokinetic profile of tranexamic acid. T0 will be defined as the injection time of tranexamic acid. The first blood sampling (T1) will be made 5 minutes after, with the garrot still in place. The garrot will then be loosened and the following blood samplings will take place at 1 minute, 5 minute, 15 minutes, 30 minutes, 1h, 2h, 4h, 8h, 12h and 24h after garrot loosening. 1ml of blood will be taken at each blood sampling. The blood will be placed in a tube suited for chemistry analysis (green tube with gel) and sent directly to the laboratory for analysis.

Secondary Outcomes

  • Knee diameter(12h)
  • Blood loss(72h)
  • Net weight of the compresses(12h)
  • Size of the blood stain on the band aid(12h)

Study Sites (1)

Loading locations...

Similar Trials